MIRM – Mirum Pharmaceuticals Inc
MIRM — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
14.16
Margin Of Safety %
-19
Put/Call OI Ratio
0.19
EPS Next Q Diff
-0.34
EPS Last/This Y
-1.35
EPS This/Next Y
1.71
Price
88.48
Target Price
125.36
Analyst Recom
1.09
Performance Q
9.52
Upside
-119.0%
Beta
0.54
Ticker: MIRM
14 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | MIRM | 88.79 | 0.70 | 0.17 | 1872 |
| 2026-03-10 | MIRM | 90.98 | 0.69 | 0.43 | 1884 |
| 2026-03-11 | MIRM | 91.8 | 0.69 | 2.00 | 1898 |
| 2026-03-12 | MIRM | 89.82 | 0.69 | 0.00 | 1897 |
| 2026-03-13 | MIRM | 89.78 | 0.69 | 0.00 | 1897 |
| 2026-03-17 | MIRM | 96.6 | 0.73 | 0.00 | 1913 |
| 2026-03-18 | MIRM | 91.62 | 0.73 | 0.00 | 1914 |
| 2026-03-19 | MIRM | 90.7 | 0.72 | 0.00 | 1912 |
| 2026-03-20 | MIRM | 88.54 | 0.71 | 0.00 | 1907 |
| 2026-03-23 | MIRM | 89.43 | 0.19 | 0.00 | 1098 |
| 2026-03-24 | MIRM | 87.83 | 0.18 | 0.00 | 1172 |
| 2026-03-25 | MIRM | 90.16 | 0.18 | 999.99 | 1186 |
| 2026-03-26 | MIRM | 88.84 | 0.19 | 0.24 | 1200 |
| 2026-03-27 | MIRM | 88.49 | 0.19 | 2.00 | 1218 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
14 items
«
‹
Current Page1 of 1
›
»
14 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | MIRM | 88.81 | -31.1 | - | -1.82 |
| 2026-03-10 | MIRM | 90.92 | -31.1 | - | -1.82 |
| 2026-03-11 | MIRM | 91.74 | -31.1 | - | -1.82 |
| 2026-03-12 | MIRM | 89.74 | -31.1 | - | -1.82 |
| 2026-03-13 | MIRM | 90.61 | -31.1 | - | -1.82 |
| 2026-03-17 | MIRM | 96.56 | -31.1 | - | -1.82 |
| 2026-03-18 | MIRM | 91.66 | -31.1 | - | -1.82 |
| 2026-03-19 | MIRM | 90.69 | -31.1 | - | -1.82 |
| 2026-03-20 | MIRM | 88.54 | -31.1 | - | -1.82 |
| 2026-03-23 | MIRM | 89.43 | -31.1 | - | -1.82 |
| 2026-03-24 | MIRM | 87.85 | -31.1 | - | -1.82 |
| 2026-03-25 | MIRM | 90.15 | -31.1 | - | -1.82 |
| 2026-03-26 | MIRM | 88.86 | -31.1 | - | -1.82 |
| 2026-03-27 | MIRM | 88.48 | -31.1 | - | -1.82 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
14 items
«
‹
Current Page1 of 1
›
»
15 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-06 | MIRM | -1.31 | 6.81 | 15.26 |
| 2026-03-09 | MIRM | -1.31 | 6.90 | 15.26 |
| 2026-03-10 | MIRM | -1.31 | 6.90 | 15.26 |
| 2026-03-11 | MIRM | -1.31 | 6.90 | 14.46 |
| 2026-03-12 | MIRM | -1.31 | 6.90 | 14.46 |
| 2026-03-13 | MIRM | -0.97 | 6.90 | 14.46 |
| 2026-03-17 | MIRM | -0.97 | 6.89 | 14.46 |
| 2026-03-18 | MIRM | -1.97 | 6.89 | 14.46 |
| 2026-03-19 | MIRM | -1.97 | 6.89 | 14.46 |
| 2026-03-20 | MIRM | -1.97 | 6.89 | 14.46 |
| 2026-03-23 | MIRM | -1.97 | 6.84 | 14.46 |
| 2026-03-24 | MIRM | -1.97 | 6.84 | 14.46 |
| 2026-03-25 | MIRM | -1.97 | 6.84 | 14.16 |
| 2026-03-26 | MIRM | -1.97 | 6.84 | 14.16 |
| 2026-03-27 | MIRM | -1.97 | 6.84 | 14.16 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
15 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.12
Avg. EPS Est. Current Quarter
-0.39
Avg. EPS Est. Next Quarter
-0.46
Insider Transactions
-1.97
Institutional Transactions
6.84
Beta
0.54
Average Sales Estimate Current Quarter
148
Average Sales Estimate Next Quarter
157
Fair Value
71.73
Quality Score
51
Growth Score
42
Sentiment Score
63
Actual DrawDown %
19
Max Drawdown 5-Year %
-40.3
Target Price
125.36
P/E
Forward P/E
PEG
P/S
10.24
P/B
14.58
P/Free Cash Flow
97.26
EPS
-0.48
Average EPS Est. Cur. Y
-1.82
EPS Next Y. (Est.)
-0.11
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-4.48
Relative Volume
1.14
Return on Equity vs Sector %
-34.8
Return on Equity vs Industry %
-18.5
EPS 1 7Days Diff
EPS 1 30Days Diff
-1.84
EBIT Estimation
◆
MIRM
Healthcare
$88.44
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
14/20
Pullback
23/25
Volume
4/15
Valuation
9/20
TP/AR
2/10
Options
4/10
RSI
43.4
Range 1M
34.8%
Sup Dist
0.6%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
8/25
Growth
17/30
Estimates
2/20
Inst/Vol
9/15
Options
4/10
EPS Yr
-244.6%
EPS NY
96.1%
52W%
71.5%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+5.3% upside
Quality
6/30
Valuation
3/30
Growth
11/25
Stability
5/10
LT Trend
0/5
Upside
+5.3%
Quality
51
MoS
-19%
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 369
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
MIRM
Latest News
—
Caricamento notizie per MIRM…
stock quote shares MIRM – Mirum Pharmaceuticals Inc Stock Price stock today
news today MIRM – Mirum Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MIRM – Mirum Pharmaceuticals Inc yahoo finance google finance
stock history MIRM – Mirum Pharmaceuticals Inc invest stock market
stock prices MIRM premarket after hours
ticker MIRM fair value insiders trading